Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly 1Q: Mounjaro, Zepbound Drive Growth | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly 1Q: Mounjaro, Zepbound Drive Growth

Demand for the company's incretin medicines outpaced supply increases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
1Q Revenues: $8.8 billion (+26%)
1Q Earnings: $2.2 billion (+67%) 
Comments: Growth in the quarter was driven by Mounjaro, Zepbound, Verzenio and Jardiance, partially offset by declines in Trulicity. Demand for the company’s incretin medicines outpaced supply increases. The company continues to expand manufacturing capacity, with the most significant production increases in 2024 expected in the second half of the year. Mounjaro sales were $1.8 billion in the quarter, compared to $568.5 million 1Q23. Verzenio sales were up 40% to $1.05 billion. Zepbound sales contributed $517.4 million in the quarter. Jardiance sales were $686.5 million, up 19%. Trulicity sales were down 26% to $1.45 million, primarily due to supply constraints and competitive dynamics. Taltz revenue increased 15% to $604.1 million. Humalog revenue increased 17% to $538.7 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters